Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.59 |
| ▸ | CES1 | P23141 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15248206 | 0.88 | CES2 (0.48) | CES2CES1TDP1FFAR1LMNA | |
| SCHEMBL5199487 | 0.88 | CA12 (0.48) | CES2CES1TDP1FFAR1LMNA | |
| SCHEMBL61847 | 0.86 | CES2 (0.47) | CES2CES1TDP1FFAR1LMNA | |
| SCHEMBL15113227 | 0.86 | GAA (0.50) | CES2CES1KMT2AMEN1JAK2 | |
| SCHEMBL24450827 | 0.86 | CES2 (0.47) | CES2CES1TDP1FFAR1LMNA | |
| SCHEMBL5200047 | 0.83 | KMT2A (0.55) | CES2CES1KMT2A | |
| SCHEMBL14519939 | 0.83 | CES2 (0.44) | CES2CES1TDP1 | |
| SCHEMBL14667938 | 0.83 | CES2 (0.55) | CES2CES1TDP1LMNAKMT2A | |
| SCHEMBL1162664 | 0.83 | CES2 (0.55) | CES2CES1TDP1LMNAKMT2A | |
| SCHEMBL24260539 | 0.80 | CES2 (0.41) | CES2CES1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228495-A1 | Tricyclic Inhibitors of Influenza Virus Endonuclease | STANFORD RES INST INT (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228495-A1 | Tricyclic Inhibitors of Influenza Virus Endonuclease | STANFORD RES INST INT (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2021195278-A1 | TRICYCLIC INHIBITORS OF INFLUENZA VIRUS ENDONUCLEASE | WEBB THOMAS R (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2020-10-29 | — | — | US | disclosed |
| US-20200267980-A1 | Herbicidally Active Pyridyl-/Pyrimidyl-Pyrimidine Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-9962382-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962382-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2010-01-07 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| US-20080051353-A1 | Avermectin And Avermectin Monosaccharide Substituted In The 4\"- And 4\" Position Respectively | SYNGENTA CROP PROTECTION, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, FLT1 | CES2 4659/4885CES1 4430/4885TDP1 4206/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CES2 1377/4885CES1 187/4885TDP1 3248/4885 |
| US-20240228495-A1 | Tricyclic Inhibitors of Influenza Virus Endonuclease | RNASEH1, RNASEL, DNASE1 | CES2 1211/4885CES1 447/4885TDP1 49/4885 |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | CES2 4310/4885CES1 3423/4885TDP1 4628/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | CES2 778/4885CES1 872/4885TDP1 1264/4885 |
| US-20080051353-A1 | Avermectin And Avermectin Monosaccharide Substituted In The 4\"- And 4\" Position Respectively | CCR6, CHRM4, CHRM5 | CES2 384/4885CES1 487/4885TDP1 2843/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CES2 4820/4885CES1 3698/4885TDP1 1869/4885 |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | CES2 994/4885CES1 343/4885TDP1 293/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | CES2 1413/4885CES1 1990/4885TDP1 2231/4885 |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | PREP, UNG, DPP4 | CES2 898/4885CES1 304/4885TDP1 275/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CES2 1377/4885CES1 187/4885TDP1 3248/4885 |
| US-20200267980-A1 | Herbicidally Active Pyridyl-/Pyrimidyl-Pyrimidine Derivatives | DPYD, PDXK, PLPBP | CES2 1602/4885CES1 1731/4885TDP1 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.